Stephen T Gordon

Array ( [id] => 19564967 [patent_doc_number] => 12139729 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-11-12 [patent_title] => Neurodegenerative disorders [patent_app_type] => utility [patent_app_number] => 17/374227 [patent_app_country] => US [patent_app_date] => 2021-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 28 [patent_no_of_words] => 17264 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17374227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17140209 [patent_doc_number] => 20210308220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-07 [patent_title] => Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody [patent_app_type] => utility [patent_app_number] => 17/212424 [patent_app_country] => US [patent_app_date] => 2021-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 154 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17212424 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16885429 [patent_doc_number] => 20210171624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/175008 [patent_app_country] => US [patent_app_date] => 2021-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13177 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17175008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17036753 [patent_doc_number] => 20210253711 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-19 [patent_title] => ANTI-MICA/B ANTIBODIES THAT BLOCK MICA/B SHEDDING AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/162585 [patent_app_country] => US [patent_app_date] => 2021-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34846 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162585 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336077 [patent_doc_number] => 20220002408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => BISPECIFIC ANTIBODY, PREPARATION METHOD THEREOF AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 17/290957 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7818 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290957 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336101 [patent_doc_number] => 20220002432 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => CD38 AND ICAM1 ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/293258 [patent_app_country] => US [patent_app_date] => 2019-11-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -140 [patent_words_short_claim] => 22 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293258 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17343686 [patent_doc_number] => 20220010017 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-13 [patent_title] => PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/293342 [patent_app_country] => US [patent_app_date] => 2019-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293342 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17170388 [patent_doc_number] => 20210324058 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-10-21 [patent_title] => NEDD9 IN PULMONARY VASCULAR THROMBOEMBOLIC DISEASE [patent_app_type] => utility [patent_app_number] => 17/290960 [patent_app_country] => US [patent_app_date] => 2019-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290960 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314498 [patent_doc_number] => 20210403546 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => HUMANIZED AND VARIANT TGF-BETA1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/290836 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45828 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290836 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17356809 [patent_doc_number] => 20220017605 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-20 [patent_title] => HUMAN ANTIBODIES TARGETING ZIKA VIRUS NS1, NS1 POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/289448 [patent_app_country] => US [patent_app_date] => 2019-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 87471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 57 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289448 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299865 [patent_doc_number] => 20210395704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => NANOBODY-GLYCAN MODIFYING ENZYME FUSION PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/289613 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17289613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17299535 [patent_doc_number] => 20210395374 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => Bispecific CD123 x CD3 Diabodies for the Treatment of Hematologic Malignancies [patent_app_type] => utility [patent_app_number] => 17/290061 [patent_app_country] => US [patent_app_date] => 2019-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43185 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17290061 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17482200 [patent_doc_number] => 20220089704 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => HUMANIZED AND STABILIZED FC5 VARIANTS FOR ENHANCEMENT OF BLOOD BRAIN BARRIER TRANSPORT [patent_app_type] => utility [patent_app_number] => 17/288445 [patent_app_country] => US [patent_app_date] => 2019-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -32 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17288445 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17336098 [patent_doc_number] => 20220002429 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => TUMOR CELL AGGREGATION INHIBITORS' FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 17/309115 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26958 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17309115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17200145 [patent_doc_number] => 20210340240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => COMBINATION OF A BIG-H3 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF SOLID TUMOR [patent_app_type] => utility [patent_app_number] => 17/283607 [patent_app_country] => US [patent_app_date] => 2019-10-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17283607 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17228673 [patent_doc_number] => 20210355229 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-18 [patent_title] => AN ANTI-OX40 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF, AND THE PHARMACEUTICAL USE [patent_app_type] => utility [patent_app_number] => 17/278259 [patent_app_country] => US [patent_app_date] => 2019-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278259 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214548 [patent_doc_number] => 20210347885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => SYNTHETIC BINDING AGENTS FOR LIMITING PERMEATION THROUGH MUCUS [patent_app_type] => utility [patent_app_number] => 17/278217 [patent_app_country] => US [patent_app_date] => 2019-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39962 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278217 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340436 [patent_doc_number] => 20230132385 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-04-27 [patent_title] => ANTIBODIES SPECIFIC TO CTLA-4 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/278261 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18340436 [patent_doc_number] => 20230132385 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2023-04-27 [patent_title] => ANTIBODIES SPECIFIC TO CTLA-4 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/278261 [patent_app_country] => US [patent_app_date] => 2019-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24396 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278261 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19411779 [patent_doc_number] => 12077586 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-03 [patent_title] => Bispecific antibodies for use in the treatment of hematological malignancies [patent_app_type] => utility [patent_app_number] => 17/277984 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 12 [patent_no_of_words] => 16656 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 108 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17277984 [rel_patent_id] =>[rel_patent_doc_number] =>)